{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:38:13Z","timestamp":1785515893632,"version":"3.56.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive transfer of virus-specific T lymphocytes (VST) is an emerging strategy for refractory viral infections in immunocompromised individuals and is being prospectively evaluated in the ALLOVISTA clinical trial. Here we describe our experience with hospital-exemption advanced therapy medicinal product (ATMP-HE) VST in six pediatric transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Six children and adolescents (median age 4.5 years, range 2.5\u201318.5) treated in two Polish centers received VST for refractory viremia after allogeneic hematopoietic stem cell transplantation: adenovirus (ADV) in three cases, EBV-driven disease (EBV\/PTLD or HL relapse with EBV reactivation) in three, including one patient with concomitant CMV\/EBV\/ADV infection. All patients had failed conventional antiviral and\/or immunochemotherapy (cidofovir, rituximab, chemotherapy). VST were generated from allo-HSCT or related donors using automated CliniMACS Prodigy Cytokine Capture System (IFN-\u03b3 CCS, Miltenyi Biotec) following antigenic stimulation with viral peptide pools and released as ATMP-HE according to the ALLOVISTA protocol. A single intravenous infusion of 1.01\u00d710\n                      <jats:sup>5<\/jats:sup>\n                      \u20131.85\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      VST (median 2.5\u00d710\n                      <jats:sup>5<\/jats:sup>\n                      ) was administered. Virological response was assessed by quantitative PCR up to 4 weeks post-infusion, acute GVHD (aGVHD) and survival were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Virological outcomes were evaluable in five patients. Four of five (80%) evaluated patients achieved at least a 1-log reduction in viral load, including two (40%) with complete clearance by week 4 (one EBV, one ADV). Two additional patients had marked but incomplete or transient viral load reductions, one patient showed minimal virological change. Despite biological activity, four children died: from progressive EBV disease (n=1), ADV infection (n=1), relapse of HL (n=1) and multi-organ failure with invasive fungal disease in a child with multi-viral infection (n=1). Two patients with complete virological responses are alive with sustained remission of viremia at the last follow-up. No new-onset or worsening aGVHD was documented after VST infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VST administered as an ATMP-HE are feasible in routine clinical practice and demonstrate rapid antiviral activity in heavily pretreated pediatric patients. However, advanced viral disease and competing complications limit overall survival, underscoring the need for earlier intervention and advocating for treatment within the ongoing ALLOVISTA trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1805803","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:59:23Z","timestamp":1775800763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hospital exemption use of virus-specific T-lymphocytes in children: early experience within the Allovista clinical trial framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Marek","family":"Ussowicz","sequence":"first","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u015al\u0119zak","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Myszka-Koz\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Gajek","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Jopek","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bukowska","sequence":"additional","affiliation":[{"name":"Department of Personalized Medicine and Cell Therapy, Regional Blood Center","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Bukowska","sequence":"additional","affiliation":[{"name":"Department of Personalized Medicine and Cell Therapy, Regional Blood Center","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Jureczek","sequence":"additional","affiliation":[{"name":"Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Jarmu\u017cek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Transplantation and Hypertension, Children\u2019s Memorial Health Institute","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczys\u0142aw","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kidney Transplantation and Hypertension, Children\u2019s Memorial Health Institute","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksymilian","family":"Der\u0119gowski","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences","place":["Pozna\u0144, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[{"name":"Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bogacz","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16053","article-title":"T\u2010cell receptor sequencing demonstrates persistence of virus\u2010specific T cells after antiviral immunotherapy","volume":"187","author":"Keller","year":"2019","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007270","article-title":"Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing","volume":"7","author":"Huisman","year":"2023","journal-title":"Blood Adv"},{"key":"B5","unstructured":"A multicenter, open-label, dose-escalation clinical trial to evaluate the safety of viral-specific T-cell (VST) therapy in the treatment of refractory viral infections after allogeneic hematopoietic stem cell transplantation (ALLOVISTA)"},{"key":"B6","unstructured":"CliniMacs prodigy manual"},{"key":"B7","unstructured":"GMP grade peptivators"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011562","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"8","author":"Dadwal","year":"2024","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with cliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J\u00a0Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281996","article-title":"Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation","volume":"108","author":"Heinz","year":"2023","journal-title":"Haematologica"},{"key":"B24","unstructured":"Ebvallo : EPAR - product information. Summary of product characteristics (SmPC)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12251","article-title":"Interferon-\u03b3 capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation","volume":"161","author":"Qasim","year":"2013","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000479238","article-title":"Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-\u03b3 Cytokine capture system","volume":"45","author":"Kim","year":"2018","journal-title":"Transfusion Med Hemotherapy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:59:29Z","timestamp":1775800769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1805803"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1805803","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1805803"}}